ORMP Oramed Pharmaceuticals Inc
Price (delayed)
$2.34
Market cap
$95.59M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.48
Enterprise value
$41.54M
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and
Highlights
ORMP's debt has shrunk by 99% YoY and by 13% QoQ
The revenue has dropped by 100% year-on-year
The gross profit has plunged by 100% YoY
Key stats
What are the main financial stats of ORMP
Market
Valuations
Earnings
Shares outstanding
40.85M
Market cap
$95.59M
Enterprise value
$41.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.64
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$12.78M
Net income
-$19.06M
EBIT
-$15.02M
EBITDA
-$14.83M
Free cash flow
-$8.43M
Per share
Balance sheet
Liquidity
EPS
-$0.48
EPS diluted
-$0.48
Free cash flow per share
-$0.21
Book value per share
$3.63
Revenue per share
$0
TBVPS
$3.8
Total assets
$155.28M
Total liabilities
$9.93M
Debt
$372,000
Equity
$146.27M
Working capital
$137.54M
Debt to equity
0
Current ratio
25.19
Quick ratio
24.97
Net debt/EBITDA
3.64
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-10.8%
Return on equity
-11.8%
Return on invested capital
-12.2%
Return on capital employed
-10%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ORMP stock price
How has the Oramed Pharmaceuticals stock price performed over time
Intraday
1.74%
1 week
8.84%
1 month
0.43%
1 year
1.74%
YTD
-3.31%
QTD
9.35%
Financial performance
How have Oramed Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.78M
Net income
-$19.06M
Gross margin
N/A
Net margin
N/A
The revenue has dropped by 100% year-on-year
The gross profit has plunged by 100% YoY
The operating income is up by 19% year-on-year and by 2.2% since the previous quarter
Growth
What is Oramed Pharmaceuticals's growth rate over time
Valuation
What is Oramed Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The P/B is 63% less than the 5-year quarterly average of 1.7 and 10% less than the last 4 quarters average of 0.7
The equity has contracted by 11% YoY and by 7% from the previous quarter
The revenue has dropped by 100% year-on-year
Efficiency
How efficient is Oramed Pharmaceuticals business performance
The company's return on invested capital has shrunk by 85% QoQ
Dividends
What is ORMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ORMP.
Financial health
How did Oramed Pharmaceuticals financials performed over time
Oramed Pharmaceuticals's total liabilities has shrunk by 83% YoY but it has increased by 3.9% QoQ
The total assets has contracted by 30% YoY and by 6% from the previous quarter
ORMP's debt is 100% lower than its equity
Oramed Pharmaceuticals's debt to equity has shrunk by 100% YoY
ORMP's debt has shrunk by 99% YoY and by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.